Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

BMY 60.27 -0.87 (-1.42%)
price chart
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK (Reuters) - Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol to Buy Amylin in $5.3 Billion Deal  Wall Street Journal
Why Bristol And Astra Teamed Up To Buy Amylin In Unique $7 Billion Deal  Forbes
Related articles »  
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Related articles »  
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA  News-Medical.net
Related articles »  
Interim results from Bristol-Myers Squibb's BMS-936558 Phase 1 study on ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with ...
Related articles »  
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL´┐Ż (dasatinib) in Philadelphia ...
Related articles »  
Bristol-Myers Immune Drug Puts Deadly Cancers on Hold in Study
The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
Related articles »  
Terminally ill patients should have access to last-chance therapies
... because of tumours in his brain. His oncologist recommends that he be given the drug, BMS-936558, saying it may help. But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and ...
Legalize pure ecstasy and sell it like alcohol, BC health chief says
DuPont, Bristol-Myers-Squibb, Novartis, etc. ... Mr. Freeh served as Vice Chairman, General Counsel, Corporate Secretary and Ethics Officer to MBNA Corporation, a bank holding company, from 2001 until its acquisition by Bank of America in January 2006.
Related articles »